CoLucid Pharmaceuticals Garners $37,100,000 Series C Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f4641675-06ea-4bb3-a620-d793304eb56b
Date
1/13/2015
Company Name
CoLucid Pharmaceuticals
Mailing Address
P.O. Box 14401 Durham, NC 27709 USA
Company Description
CoLucid Pharmaceuticals is an innovative biotechnology company focusing on therapies for central nervous system (CNS) disorders. CoLucid is leading a paradigm shift in migraine therapy with the clinical development of a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA).
Website
http://www.colucid.com
Transaction Type
Venture Equity
Transaction Amount
$37,100,000
Transaction Round
Series C
Proceeds Purposes
Proceeds from the Series C will be used to fund the Company’s Phase 3 program for oral Lasmiditan, to include the first pivotal study, COL MIG-301 SAMURAI, for the acute treatment of migraine.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor